Depot-leuprolide acetate for treatment of paraphilias: A report of twelve cases

Archives of Sexual Behavior

Volumn 30, Issue 4, 2001, Pages 409-422

  Krueger, Richard B ^a   Kaplan, Meg S ^a  

^a Columbia Univ New York New York ^*  (United States)

Author keywords

antiandrogens; leuprolide acetate; LHRH agonists; paraphilia; sex offenders

Indexed keywords

LEUPRORELIN; ANTIANDROGEN; FOLLITROPIN; LUTEINIZING HORMONE; TESTOSTERONE;

ADULT; ARTICLE; BONE DEMINERALIZATION; CLINICAL ARTICLE; CLINICAL OBSERVATION; DEPRESSION; DISEASE CONTROL; DRUG TOLERABILITY; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FOLLOW UP; GYNECOMASTIA; HUMAN; LONG TERM CARE; MALE; MEASUREMENT; NAUSEA; PATIENT; SELF REPORT; SEXUAL BEHAVIOR; SEXUAL DEVIATION; SEXUAL DYSFUNCTION; SUSPENSION; TIME; VOMITING; CASE REPORT; CHEMICALLY INDUCED DISORDER; DELAYED RELEASE FORMULATION; METABOLISM; MIDDLE AGED; OSTEOLYSIS;

ADULT; ANDROGEN ANTAGONISTS; BONE RESORPTION; DELAYED-ACTION PREPARATIONS; FOLLICLE STIMULATING HORMONE; FOLLOW-UP STUDIES; HUMANS; LEUPROLIDE; LUTEINIZING HORMONE; MALE; MIDDLE AGED; PARAPHILIAS; TESTOSTERONE;

EID: 0035434633     PISSN: 00040002     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1010213432606     Document Type: Article

References (27)

1. American Psychiatric Association. (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn., APA, Washington, DC.
2. Appelbaum, P. S., and Gutheil, T. G. (1991). Clinical Handbook of Psychiatry and the Law, 2nd edn., Williams & Wilkins, Baltimore.
3. Ascoli, M., and Segaloff, D. L. (1996). Adenohypophyseal hormones and their hypothalamic releasing factors. In Hardman, J., and Limbird, L. (eds.), Goodman & Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, pp. 1363-1382.
4. Bradford, J. M. (1985). Organic treatment for the male sexual offender. Behav. Sci. Law 3: 355-375.
5. Bradford, J. M. (1988). Organic treatment for the male sexual offender. In Prentky, R., and Quinsey, V. (eds.), Human Sexual Aggression: Current Perspectives, The New York Academy of Sciences, New York, pp. 193-202.
6. Bradford, J. M. (1998). Treatment of men with paraphilia. N. Engl. J. Med. 338: 464, 465.
7. Cooper, A. J., and Cernovsky, Z. Z. (1994). Comparison of cyproterone acetate (CPA) and leuprolide acetate (LHRH agonist) in a chronic pedophile: A clinical case study. Biol. Psychiatry 36: 269-271.
8. Daniell, H. W., Dunn, S. R., Ferguson, D. W., Lomas, G., Niazi, Z., and Stratte, P. T. (2000). Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J. Urol. 163: 181-186.
9. Diamond, T., Campbell, J., Bryant, C., and Lynch, W. (1998). The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostatic carcinoma. Cancer 83: 1561-1566.
10. Dickey, R. (1992). The management of a case of treatment-resistant paraphilia with a long-acting LHRH agonist. Can. J. Psychiatry 37: 567-569.
11. Gijs, L., and Gooren, L. (1996). Hormonal and psychopharmacological interventions in the treatment of paraphilias: An update. J. Sex Res. 33: 273-290.
12. Heim, N. (1981). Sexual behavior of castrated sex offenders. Arch. Sex. Behav. 10: 11-19.
13. Hornstein, M. D., Surrey, E. S., Weisberg, G. W., and Casino, L. A. (1998). Leuprolide acetate depot and hormonal add-back in endometriosis: A 12-month study. Obstet. Gynecol. 91: 16-24.
14. Kafka, M. P., and Prentky, R. A. (1998). Attention-deficit/hyperactivity disorder in males with paraphilias and paraphilia-related disorders: A comorbidity study. J. Clin. Psychiatry 59: 388-396.
15. Rachman, M., Garfield, D. A. S., Rachman, I., and Cohen, R. (1999). Lurpon-induced mania. Biol. Psychiatry 45: 243, 244.
16. Raymond, N. C., Coleman, E., Ohlerking, F., Christenson, G. A., and Miner, M. (1999). Psychiatric comorbidity in pedophilic sex offenders. Am. J. Psychiatry 156: 786-788.
17. Rich, S. S., and Ovsiew, F. (1994). Leuprolide acetate for exhibitionism in Huntington's disease. Mov. Disord. 9: 353-357.
18. Rosler, A., and Witztum, E. (1998). Treatment of men with paraphilia with a long-acting analogue of gonadotropin-releasing hormone. N. Engl. J. Med. 338: 416-422.
19. Rousseau, L., Couture, M., Dupont, A., Labrie, F., and Couture, N. (1990). Effect of combined androgen blockade with and LHRH agonist and flutamide in one severe case of male exhibitionism. Can. J. Psychiatry 35: 338-341.
20. Rousseau, L., Dupont, A., Labrie, F., and Couture, M. (1988). Sexuality changes in prostate cancer patients receiving antihormonal therapy combining the antiandrogen flutamide with medical (LHRH agonist) or surgical castration. Arch. Sex. Behav. 17: 87-98.
21. Smith, J. A., Glode, L. M., Max, D. T., Wettlaufer, J. N., Anbar, D., Stein, B. S., Jagst, C. L., Glass, A. G., and Murphy, G. P. (1985). Clinical effects of gonadotrophin-releasing hormone analogue in metastatic carcinoma of prostate. Urology 25: 106-114.
22. Surrey, E. S., and the Add-Back Consensus Working Group. (1999). Add-back therapy and gonadotropin-releasing hormone agonists in the treatment of patients with endometriosis: Can a consensus be reached? Fertil. Steril. 71: 420-424.
23. Thibaut, F., Cordier, B., and Kuhn, J.-M. (1993). Effect of a long-lasting gonadotrophin hormone-releasing hormone agonist in six cases of severe male paraphilia. Acta Psychiatr. Scand. 87: 445-450.
24. Thibaut, F., Cordier, B., and Kuhn, J.-M. (1996). Gonadotrophin hormone releasing hormone agonist in cases of severe paraphilia: A lifetime treatment? Psychoneuroendocrinology 21: 411-419.
25. Townsend, M. F., Sanders, W. H., Northway, R. O., and Graham, S. D. (1997). Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer 79: 545-550.
26. Warnock, J. K., Bundren, J. C., and Morris, D. W. (1998). Sertraline in the treatment of depression associated with gonadotropin-releasing hormone agonist therapy. Biol. Psychiatry 43: 464, 465.
27. Wei, J. T., Gross, M., Jaffe, C. A., Gravlin, K., Lahaie, M., Faerber, G. J., and Cooney, K. A. (1999). Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology. 54: 607-611.